

Index

ABANDONMENT

Novelty, nonobviousness and double patenting, **4:45**

ABBREVIATED NEW DRUG APPLICATION

Infringement, filing ANDA or paper NDA as infringing act, **6:28**

ACTIVE INDUCEMENT

Infringement (this index)

AMERICA INVENTS ACT (AIA) OF 2011

Derivation proceedings and derived patents suits, **8:38**

Infringement, prior use personal defense, **6:30.50**

Inter partes review, **8:41**

Novelty, nonobviousness and double patenting
documentary prior art, U.S.
practice, **4:34.50**

effect of, **4:16.70**

introduction, **4:1.70**

prior art, **4:23.70**

Office of Patent and Trademark, **8:38 to 8:41**

Post-grant review, **8:40**

Supplemental examination, **8:39**

AMINO ACID SEQUENCES

Sequence Listings (this index)

Office of Patent and Trademark, **App F2(11)**

Representation, **8:11**

ANCILLARY BIOLOGICAL MATERIALS

Claim drafting, **7:18**

ANIMALS

Copyright protection for plant and animal phenotypes, **14:10**

Disclosure, animal data, **5:16, 5:17**

ANIMALS—Cont'd

European Patent Convention, examination guidelines—plant or animal varieties excluded from patentability, **App J3**

Generic Animal Drug and Patent Term Restoration Act, **14:13**

Novelty, nonobviousness and double patenting, animal testing versus clinical testing, **4:39**

PTO notice, animals—patentability, **App H4**

Utility patent protection of animal varieties, **9:3 to 9:6**

“ANTAMANIDE” CASE

Germany, Federal Republic of, **13:10**

ANTIBODIES

Monoclonal Antibodies (this index)

Patent eligibility issues, **3:7**

ANTIGENS

Claim drafting, **7:23**

ANTITRUST MATTERS

Infringement, sham litigation, **6:35**

International matters, **13:13 to 13:17**

Licenses and licensing, **10:32**

APPLICATIONS

Animal varieties, utility patent protection of, **9:4**

Examining patent applications with respect to 35 U.S.C Section 112, chemical/biotechnical applications, **App H15**

Office of Patent and Trademark (this index)

Plant Variety Protection Certificate, **App G4**

APPRECIATION

Novelty, nonobviousness and double patenting, **4:44**

- ARTICLE 53**
European Patent Convention, exceptions to patentability, **App J1**
- ARTIFICIAL INTELLIGENCE**
Novelty, nonobviousness and double patenting, **4:51**
- “ASEXUALLY REPRODUCED” VARIETIES**
Plants and plant patents, **11:10**
- ASSERTED UTILITY**
Disclosure, **5:10**
- ASSIGNMENT**
Ownership, **10:2 to 10:5**
- ATOMIC ENERGY ACT**
Office of Patent and Trademark, **8:27**
- AUSTRALIA**
Generally, **13:15**
- AUTHENTICATION**
Office of Patent and Trademark interference practice, **8:37.40**
- BACTERIA**
Plants and plant patents, **11:3**
- “BAKER’S YEAST” CASE**
Germany, Federal Republic of, **13:7**
- BENEFIT TO SOCIETY**
Disclosure, utility, **5:9**
- BERGY DECISION**
Patentability of living organisms, **2:4, 2:5**
- “BEST MODE” REQUIREMENT**
Disclosure, **5:29, 5:30**
- BIOCHEMICALS**
Patent eligibility issues, **3:8**
- BIOCHEMISTRY CASES**
Classical biochemistry infringement cases, **6:8**
- BIOLOGICAL PRODUCTS**
Approval, effect of patents on infringement, biosimilars, **6:33.50**
- BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)**
Copyright protection, exclusivity, **14:17**
- BIOSIMILARS**
Approval, effect of patents on infringement, **6:33.50**
- BIOTECHNOLOGICAL PROCESS PATENTS**
House report on, **App H12**
- BREADTH OF CLAIMS**
Plants and plant patents, **11:16**
- BREEDING**
Claim drafting, **7:35**
Plant breeding, utility patent protection of, **9:2**
- BUDAPEST TREATY**
Deposit of Microorganisms (this index)
Disclosure, deposits, **5:34, 5:50, 5:55**
- CANADA**
Microbiology cases, **13:17**
- CCPA**
Patentability of living organisms, **2:5 to 2:7**
- CELL BIOLOGY CASES**
Claim drafting, **7:25 to 7:38**
Classical cell biology infringement cases, **6:9**
Disclosure, **5:7.10, 5:24, 5:66**
Living organisms, **3:4**
Nonobviousness standard, **4:17**
- CELL CULTURES**
Claim drafting, untransformed eukaryotic cell cultures, **7:37**
Patents, **1:5, 1:6**
- CELL LINES**
Hybridoma Cell Lines (this index)
Tangible property rights, **14:11**
- CERTAINTY AND DEFINITENESS**
Claim drafting, **7:2 to 7:6**

INDEX

CHAKRABARTY DECISION

Patentability of living organisms, **2:3, 2:6, 2:8**

CHANGES

Plants and plant patents, changes in plant patent protection under UPOV, **11:23**

CHEMICAL CASES

Nonobviousness standard, **4:21.60**

CHEMICAL COMPOSITIONS OR COMPOUNDS

Interim examination guidelines for species claims to chemical compositions based on single prior art reference, **App H14**

Nonobviousness standard, structural similarities of chemical compounds, **4:6**

CLAIM DRAFTING

Generally, **7:1 et seq.**

Ancillary biological materials, **7:18**

Antigens, **7:23**

Breeding methods, **7:35**

Cell biology inventions, **7:25 to 7:38**

Cell cultures, untransformed eukaryotic cell cultures, **7:37**

Certainty and definiteness, **7:2 to 7:6**

Classification of organisms, **7:4**

Completeness, **7:5**

Construction, **7:8.75**

Cultivation methods, **7:31**

Definiteness requirement, **7:2 to 7:6**

Eukaryotic cell cultures, untransformed eukaryotic cell cultures, **7:37**

Fermentation methods, **7:25 to 7:29**

“Fingerprint” claims, **7:9**

Functional limitations, **7:7**

Genes, structural genes and their proteins, identification of, **7:16**

Genetic engineering methods, **7:17**

Haptens, **7:23**

Hybridoma cell lines, **7:21**

Identifying structural genes and their proteins, **7:16**

Immunology inventions, **7:19 to 7:24**

Infringement, **7:11**

CLAIM DRAFTING—Cont’d

Isolates, pure cultures of microbial isolates, **7:32**

Isolation methods, **7:31**

“Jepson” claims, **7:14**

Limitations in claims, **7:7 to 7:8.50**

“Markush group” claims, **7:13**

Microbiology inventions, **7:25 to 7:38**

Mixed cultures, **7:33**

Molecular biology inventions, **7:15 to 7:18**

Monoclonal antibodies, **7:20**

Mutated microorganisms, **7:35, 7:36**

Negative limitations in claims, **7:8**

Nutrient media, **7:27**

Office of Patent and Trademark, **8:2 to 8:18.50**

Operating conditions, **7:28**

Organ cultures, **7:38**

“Organism-plus-carrier” claims, **7:34**

Preamble limitations in claims, **7:8.50**

“Product-by-process” claims, **7:10 to 7:12**

Proteins, structural genes and their proteins, identification of, **7:16**

Pure cultures of microbial isolates, **7:32**

Reagents and test kits, **7:24**

Special claim formats, **7:9 to 7:14**

Structural genes and their proteins, identification of, **7:16**

Supplementary protection, **7:29**

Taxonomic classification of organisms, **7:4**

Terms of degree, **7:3, 7:4**

Test kits, **7:24**

Tissue cultures, **7:38**

Untransformed eukaryotic cell cultures, **7:37**

CLAIMS

As to particular claims, see specific index topics

Drafting. **Claim Drafting** (this index)

- CLAIMS—Cont'd**
Percentage Sequence Identity Language (this index)
- CLASSIFICATION OF ORGANISMS**
 Claim drafting, **7:4**
- CLASSIFICATION SCHEME**
Office of Patent and Trademark (this index)
- CLINICAL MATTERS**
 Disclosure, clinical data, **5:15**
 Novelty, nonobviousness and double patenting, animal testing versus clinical testing, **4:39**
- COLLABORATION**
 Licenses and licensing, **10:25**
- COMPARATIVE STUDY REPORT**
 Trilateral Project 24.1, comparative study on biotechnology patent practices, **App J5**
- COMPLETENESS**
 Claim drafting, **7:5**
- COMPUTER-IMPLEMENTED STEPS**
 Processes involving, patent eligibility issues, **3:14**
- CONCEALMENT**
 Novelty, nonobviousness and double patenting, **4:45**
- CONCEPTION**
 Novelty, nonobviousness and double patenting, **4:42**
 Plants and plant patents, **11:13**
- CONFERENCES**
 Novelty, nonobviousness and double patenting, **4:29**
- CONFIDENTIAL DOCUMENTS**
 Novelty, nonobviousness and double patenting, **4:31**
- CONSENT**
 Infringement, Federal authorization and consent, **6:32**
- CONSIDERATION**
 Licenses and licensing, **10:19 to 10:23**
- CONSOLIDATION OF PROCEEDINGS**
 Patentability of living organisms, **2:7**
- CONSTITUTIONAL LAW**
 Animal varieties, utility patent protection of, **9:3**
- CONSTRUCTION AND INTERPRETATION**
 Claim drafting, **7:8.75**
 Infringement litigation, interpretation of claim in, **6:8 to 6:13**
 Literal infringement, **6:2**
 Patentability of living organisms, static v. dynamic construction, **2:11**
- CONTINUED EXAMINATION**
 Office of Patent and Trademark, **8:33**
- CONTRACTOR IMMUNITY**
 Pandemic Readiness and Emergency Preparedness Act infringement, **6:36**
- CONTRIBUTORY INFRINGEMENT**
Infringement (this index)
- CONVENTIONS**
 Disclosure, deposits under, **5:60, 5:61**
European Patent Convention (this index)
 Plant patent protection outside of conventions, **13:4**
- COPYRIGHT PROTECTION**
 Animal phenotypes, **14:10**
 Biologics Price Competition and Innovation Act (BPCIA), **14:17**
 DNA sequences, **14:3 to 14:6**
 Gene sequences or molecules, **14:2 to 14:9**
 Molecules, **14:2 to 14:9**
 Novel gene sequences, **14:5, 14:9**
 Nucleotide combinations, **14:8**
 Plant and animal phenotypes, **14:10**

INDEX

COPYRIGHT PROTECTION

—Cont'd

Proteins, **14:6**

CORROBORATION

Office of Patent and Trademark
interference practice, **8:37.20**

CREDIBILITY

Disclosure, standard of proof of oper-
ability, **5:14**

CRITICAL DATE OF INVENTION

Novelty, nonobviousness and double
patenting, **4:25**

CRYSTALLINE PAROXETINE HYDROCHLORIDE HEMIHYDRATE

Patent eligibility issues, **3:16**

CULTIVATION

Claim drafting, **7:31**

Plants and plant patents, varieties
found in “cultivated state,”
11:11

DATE

Time or Date (this index)

DEFENSES

Infringement, **6:26 to 6:32**

DEFINITENESS REQUIREMENT

Claim drafting, **7:2 to 7:6**

DEPOSIT OF MICROORGANISMS

Budapest Treaty

generally, **App B1 to App B4**

international depositary authorities
under, **App B4**

Office of Patent and Trademark,
below

parties to treaty, **App B3**

Disclosure (this index)

European Patent Convention

generally, **App D1 to App D5**

notice on recognition of
microbiological experts for
purpose of EPC Rule 28, **App
D5**

notice re. European patent applica-
tions and European patents in

DEPOSIT OF MICROORGANISMS

—Cont'd

European Patent Convention

—Cont'd

which reference is made to
microorganisms, **App D4**

Rule 28 (amended), **App D2**

Rule 28 (original), **App D1**

Rule 28a, **App D3**

European patents

European Patent Convention,
above

patent cooperation treaty, informa-
tion for PCT applicants
designating—European Patent
Organization, **App C4**

Manual of Patent Examining Proce-
dure § 608.01(p), **App A1**

Office of Patent and Trademark

see also lines throughout this topic
advance notice of proposed
rulemaking on deposit of
biological materials, **App
A2(2)**

Budapest Treaty

certification of deposits made
under Treaty, notice on
request for, **App A5**

designation of international
depositary authorities under
Treaty, notice of, **App A3**
entry into force of Treaty, notice
on, **App A4**

disclosure of deposit of biological
materials, **5:35**

draft policy statement on deposit of
biological materials, **App
A2(1)**

notice

Budapest Treaty, above in this
group

designation of international
depositary authorities under
the Budapest Treaty, **App
A3**

final rule on deposit of biologi-
cal materials for patent
purposes, **App A2(4)**

proposed rulemaking on deposit
of biological materials for

DEPOSIT OF MICROORGANISMS

—Cont'd

- Office of Patent and Trademark
 - Cont'd
 - notice—Cont'd
 - patent purposes, **App A2(3)**
 - rules and regulations, changes to
 - time period for making necessary deposit of biological material, **App A6**
- Patent cooperation treaty
 - generally, **App C1 to App C4**
 - applicants' guide: Annex M1: references to deposits of microorganisms, **App C2**
 - applicants' guide, Annex M3, Form PCT/RO/134: Microorganisms, **App C3**
 - European Patent Organization, information for PCT applicants designating, **App C4**
 - microbiological inventions, **App C1**
- Rule on deposit of biological materials for patent purposes, 37 C.F.R. §§ 1.801 to 1.809, **App A2**
- Rules on applications, amendment, **App A7**
- Specification supplementation.
 - Disclosure** (this index)
- Suggestion for deposit of biological material, **App A1(1)**

DERIVATION PROCEEDINGS AND DERIVED PATENTS SUITS

- Plants and plant patents, derivation as element of infringement, **11:18**
- 2011 America Invents Act (AIA), **8:38**

DESCRIPTION

- Disclosure** (this index)

DESIGN PATENTS

- Animals and plants, design patent protection of ornamental features of, **9:5**

DIAGNOSTIC METHODS

- Patent eligibility issues, **3:11**

DILIGENCE

- Novelty, nonobviousness and double patenting, **4:43**

DIRECT INFRINGEMENT

- Generally, **6:14 to 6:16**

DISCLOSURE

- Generally, **5:1 et seq.**
- Animal data, **5:16, 5:17**
- Asserted or well-established utility, **5:10**
- Benefit to society, utility, **5:9**
- “Best mode” requirement, **5:29, 5:30**
- Budapest treaty, deposits under, **5:34, 5:50, 5:55**
- Case law
 - cell biology cases, **5:7.10, 5:24, 5:66**
 - description requirement, generally, **5:7 to 5:7.40**
 - immunology cases, **5:7.20, 5:25, 5:65**
 - medical device cases, **5:28.50**
 - microbiology cases, **5:7.10, 5:7.30**
 - miscellaneous biotechnology cases, **5:7.40**
 - molecular biology cases, **5:7.30, 5:26, 5:64**
 - pharmaceutical cases, **5:28.50**
 - time of deposit of biological materials, **5:40 to 5:43**
- Cell biology cases, **5:7.10, 5:24, 5:66**
- Clinical data, **5:15**
- Conventions, deposits under, **5:60, 5:61**
- Credibility, standard of proof of operability, **5:14**
- Date when deposit must be made available to public, **5:45 to 5:47**
- Deposit of biological materials
 - generally, **5:31 to 5:62**
 - Budapest treaty summary, **5:34**
 - description in specification, **5:44**
 - history, **5:32**
 - location for deposit, **5:54 to 5:56**
 - new deposit rules, **5:56**

INDEX

DISCLOSURE—Cont'd

Deposit of biological materials
—Cont'd
public availability restrictions,
5:48 to 5:52
specification, means of
supplementing, **5:31 to 5:62**
summary of deposit rules, **5:33**
35 U.S.C.A. § 112, satisfaction,
5:35 to 5:39, 5:59
35 U.S.C.A. § 114, authority of
PTO to require specimens,
5:62
time of deposit, **5:40 to 5:43**
time when deposit must be made
available to public, **5:45 to
5:47**
treaties and conventions, **5:60,
5:61**
viability and operability issues,
5:53

Description
generally, **5:2 to 5:7.40**
biotechnology case law, **5:7 to
5:7.40**
deposits of biological materials,
5:44, 5:59
1998 interim guidelines, **5:3**
1999 revised interim guidelines,
5:4
training materials, **5:6, 5:6.50**
2001 revised written description
guidelines, **5:5**
written description, **5:5, 5:63 to
5:66**

Enablement, generally, **5:8 to 5:28**
European patent convention, **5:61**

Evidence
animal data, **5:16, 5:17**
presumption of utility, **5:13**
standard of proof of operability,
5:14
therapeutic utility, **5:15, 5:16, 5:18**

Ex parte Lundak, **5:41**
Final deposit rules, **5:52**
Fully genotyped organisms, **5:38**
Genetic engineered organisms, **5:39**
Genotyped organisms, **5:38**
Great Britain, **13:11, 13:12**

DISCLOSURE—Cont'd

Heightened written description,
5:2.10
Human therapeutic utility, **5:15, 5:16,
5:18**
Hybridoma cell lines, **5:37**
Immunology cases, **5:7.20, 5:25,
5:27, 5:65**
Injurious inventions and utility, **5:19
to 5:20.10**
In vitro data, **5:18**
Isolated and mutated
microorganisms, generally, **5:36**
Licenses and licensing, **10:28**
Limitations or restrictions on public
availability, **5:48 to 5:52**
Lists and listing, sequence listings,
5:67 to 5:69
Lundak case, **5:40 to 5:43**
Medical device cases, **5:28.50**
Microbiology cases, **5:7.10, 5:24,
5:66**
Molecular biology cases, **5:7.30,
5:26, 5:64**
Molecular immunology cases, **5:27**
Mutated microorganisms, generally,
5:36
New deposit rules, deposits under,
5:56
Office of Patent and Trademark
deposit of biological materials,
5:35
specimens, PTO authority to
require, **5:62**
Operable inventions, **5:12, 5:18, 5:21
to 5:28.50**
Patent cooperation treaty, **5:60**
Pharmaceutical cases, **5:28.50**
Plants and plant patents, **11:14**
Postfiling deposits, **5:43**
Post-Lundak problems with postfiling
deposits, **5:43**
Pre-Lundak case law, **5:40**
Presumption of utility, **5:13**
Prima face case of inoperability, **5:13**
Proof. Evidence, above
Public policy, inventions contrary to,
5:19, 5:20

DISCLOSURE—Cont'd

- Restrictions on public availability, **5:48 to 5:52**
- Safety of invention, **5:20**
- Sequence listings, **5:67 to 5:69**
- Specific and substantial utility, **5:11**
- Specification, deposit of
 - microbiological materials as means of supplementing, **5:31 to 5:56**
- Standard of proof of operability, **5:14**
- Substantial utility, **5:11**
- Therapeutic utility, evidence of, **5:15, 5:16, 5:18**
- 35 U.S.C.A. § 112, deposit of biological materials, **5:35 to 5:39, 5:59**
- 35 U.S.C.A. § 114, deposit of biological materials, **5:62**
- Time or date when deposit must be made available to public, **5:45 to 5:47**
- Training materials
 - 2000 written description training materials, **5:6**
 - 2008 written description training materials, **5:6.50**
- Treaties, deposits under, **5:34, 5:50, 5:55, 5:60, 5:61**
- Unsafe inventions, **5:20**
- Utility, generally, **5:8 to 5:21**
- Veterinary utility, animal data as proof of, **5:17**
- Viability, **5:53**
- Well-established utility, **5:10**
- Written description, **5:2.10, 5:5, 5:63 to 5:66**

DISTINCTNESS

- Office of Patent and Trademark, **8:22**
- Plants and Plant Patents** (this index)

DNA

- Copyright protection, DNA sequences, **14:3 to 14:6**
- MPEP § 708.02, petition to make special (Section VII. inventions relating to recombinant DNA), **App H6**

DNA—Cont'd

- Patent eligibility issues, **3:6**

DNA SEQUENCES

- Copyright protection, **14:3 to 14:6**

DOCUMENTARY PRIOR ART

- Novelty, nonobviousness and double patenting, **4:27 to 4:35**

DOUBLE PATENTING

- Novelty, Nonobviousness and Double Patenting** (this index)

DRAFTING CLAIMS

- Claim Drafting** (this index)

DRAWINGS

- Office of Patent and Trademark, **8:16 to 8:18.50**

DRUG APPROVALS

- Exclusive drug approvals, **14:12 to 14:16**
- Infringement, **6:33**

EASTERN BLOC

- Statutory protection, **13:1**

ELECTRONIC PUBLICATIONS

- Novelty, nonobviousness and double patenting, **4:32**

EMPLOYEES

- Ownership** (this index)

ENABLEMENT

- Disclosure** (this index)
- Novelty, nonobviousness and double patenting, “enabling” character, **4:27**
- Utility and injurious inventions, **5:20.10**

ENERGY INVENTIONS

- Ownership, **10:7**

EQUITABLE CONDUCT

- Office of Patent and Trademark, standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**

EQUIVALENTS, DOCTRINE OF

- Infringement** (this index)

INDEX

ERYTHROPOIETIN

Infringement (this index)

ESTOPPEL

Infringement, file wrapper estoppel,
6:5 to 6:7

EUKARYOTIC CELL CULTURES

Claim drafting, untransformed
eukaryotic cell cultures, **7:37**

EUROPEAN PATENT CONVENTION

Article 53: exceptions to patent-
ability, **App J1**

Deposit of Microorganisms (this
index)

Examination guidelines
microorganisms, inventions relat-
ing to, excerpts from Chapter
II, **App J2**

plant or animal varieties excluded
from patentability, excerpts
from Chapter IV, **App J3**

Microorganisms
Deposit of Microorganisms (this
index)
examination guidelines, inventions
relating to, excerpts from
Chapter II, **App J2**

Plant or animal varieties excluded
from patentability, excerpts from
Chapter IV, examination
guidelines, **App J3**

EUROPEAN PATENTS

Animals, utility patent protection
under European patents, **9:6**

Deposit of Microorganisms (this
index)

Disclosure, European patent conven-
tion, **5:61**

EVIDENCE

Disclosure (this index)

EXAMINATION AND EXAMINATION GUIDELINES

European Patent Convention (this
index)

Interim examination guidelines for
species claims to chemical com-

EXAMINATION AND

EXAMINATION GUIDELINES

—Cont'd

positions based on single prior
art reference, **App H14**

**Manual of Patent Examining Pro-
cedure** (this index)

Office of Patent and Trademark
(this index)

Training materials for examining
patent applications with respect
to 35 U.S.C Section 112,
chemical/biotechnical applica-
tions, **App H15**

2011 America Invents Act (AIA),
supplemental examination, **8:39**

Utility examination guidelines, **App
H26**

EXCLUSIVE DRUG APPROVALS

Generally, **14:12 to 14:16**

EXHAUSTION DEFENSE

Infringement, **6:29**

EX PARTE MATTERS

Disclosure, ex parte Lundak, **5:41**

Patentability of living organisms, **2:3,
2:4**

EXPECTATION OF SUCCESS

Nonobviousness, standard of, **4:10 to
4:12**

EXPERIMENTAL USE DEFENSE

Infringement, **6:26**

EXPIRATION ISSUES

Infringement, **6:22**

EXTENSION OF PATENT TERM

Infringement, **6:23**

Licenses and licensing, **10:27**

FEDERAL GOVERNMENT

Licenses and Licensing (this index)

FEDERAL GOVERNMENT EMPLOYEES

Ownership, **10:10**

FERMENTATION

Patent eligibility issues, **3:10**

FERMENTATION PROCESSES

Claim drafting, **7:25 to 7:29**

Living organisms, **3:4**

FESTO DECISION

Infringement, **6:6, 6:7**

FIELD TESTING

Novelty, nonobviousness and double patenting: laboratory versus field testing, **4:40**

FILE WRAPPER ESTOPPEL

Infringement, **6:5 to 6:7**

FINAL DEPOSIT RULES

Disclosure, **5:52**

FINAL REJECTION

Office of Patent and Trademark, **8:32**

“FINGERPRINT” CLAIMS

Claim drafting, **7:9**

FIRST INVENTOR DEFENSE

Infringement, **6:30**

FLOOK DECISION

Patentability of living organisms, “unforeseen technologies,” **2:9**

FOREIGN COUNTRIES

International Matters (this index)

FORMAL DRAWINGS

Office of Patent and Trademark, **8:16 to 8:18.50**

FRANCE

International matters, **13:19**

FULLY GENOTYPED ORGANISMS

Disclosure, **5:38**

FUNCTIONAL LIMITATIONS

Claim drafting in claims, **7:7**

GATT

Infringement, implementing legislation, **6:19**

Office of Patent and Trademark, post-GATT transitional practice, **8:26, 8:32**

GENERAL AGREEMENT ON TARIFFS AND TRADE

GATT (this index)

GENERIC ANIMAL DRUG AND PATENT TERM RESTORATION ACT

Exclusive drug approvals, **14:13**

GENES

Claim drafting, structural genes and their proteins, identification of, **7:16**

Copyright protection for gene sequences or molecules, **14:2 to 14:9**

Genetic Engineering (this index)

GENETIC ENGINEERING

Animals, utility patent protection under European patents, **9:6**

Claim drafting, **7:17**

Disclosure, **5:39**

Patents, generally, **1:3, 1:7**

Plant varieties, utility patent protection of, **9:2**

GENETIC INVENTIONS

PTO policy statement on, **App H22**

GENOTYPED ORGANISMS

Disclosure, **5:38**

GENUS AND SPECIES

RESTRICTIONS

Office of Patent and Trademark, **8:25**

GEOGRAPHIC SCOPE OF U.S.

PATENTS

Infringement, **6:25**

GERMANY, FEDERAL REPUBLIC OF

Generally, **13:5 to 13:10**

“Antamanide” case, **13:10**

“Baker’s yeast” case, **13:7**

“Red dove” case, **13:6**

“Rose mutation” case, **13:8**

“6-APA” case, **13:9**

GREAT BRITAIN

Microbiological processes and microorganisms, **13:11, 13:12**

INDEX

GROWTH HORMONES

Infringement (this index)

GUARANTEES

Infringement, patent term guarantees,
6:20

GUIDELINES

Patent eligibility issues, **3:17**

HAPTENS

Claim drafting, **7:23**

HISTORICAL BACKGROUND

Patent eligibility issues, **2:2**

HORMONES

Infringement (this index)

HOUSE REPORT ON

BIOTECHNOLOGICAL PROCESS PATENTS

Generally, **App H12**

HUMANS

Patentability of living organisms,
2:14

HUMAN THERAPEUTIC UTILITY

Disclosure, **5:15**

HYBRID CELL CULTURES

Patents, **1:6**

HYBRIDOMA CELL LINES

Claim drafting, **7:21**

Disclosure, **5:37**

IDENTIFICATION

Claim drafting, identifying structural
genes and their proteins, **7:16**

Licensed rights, **10:10**

IDENTITY LANGUAGE IN CLAIMS

**Percentage Sequence Identity
Language** (this index)

IMMUNOLOGY CASES

Claim drafting, **7:19 to 7:24**

Classical immunology infringement
cases, **6:10**

Disclosure, **5:7.20, 5:25, 5:27, 5:65**

Infringement (this index)

IMMUNOLOGY CASES—Cont'd

Molecular Immunology Cases (this
index)

Nonobviousness standard, **4:18, 4:20**

IMPLIED LICENSES

Generally, **10:34**

IMPLIED OBLIGATION TO ASSIGN

Ownership, **10:3 to 10:5**

INDEPENDENT INVENTIONS

Office of Patent and Trademark, **8:21**

INDUCEMENT

Infringement (this index)

INEQUITABLE CONDUCT

Cases, **8:31.50**

Office of Patent and Trademark, stan-
dards of inequitable conduct in
biotechnology patent and prose-
cution litigation, **8:31**

INFRINGEMENT

Generally, **6:1 et seq.**

Active inducement and contributory
infringement

generally, **6:18**

plants and plant patents, **11:21**

America Invents Act (AIA) of 2011,
prior use personal defense,
6:30.50

ANDA or paper NDA, filing as
infringing act, **6:28**

Antibodies, immunometric assays
employing monoclonal antibod-
ies, **6:12**

Antitrust matters, sham litigation,
6:35

Biochemistry infringement cases, **6:8**

Biological product approval, effect of
patents on, biosimilars, **6:33.50**

Biology infringement cases, **6:8**

Cell biology infringement cases, **6:9**

Claim drafting, **7:11**

Classic “experimental use” defense,
6:26

Consent, Federal authorization and
consent, **6:32**

INFRINGEMENT—Cont'd

- Construction or interpretation of claim in biotechnology patent infringement litigation, **6:8 to 6:13.50**
- Contributory infringement generally, **6:17**
 - active inducement and contributory infringement, above
- Defenses, **6:26 to 6:32**
- Direct infringement, **6:14 to 6:16**
- Drug approval process, effect of patents on, **6:33**
- Equivalents, doctrine of generally, **6:3**
 - reverse doctrine of equivalents, **6:4**
- Estoppel, file wrapper estoppel, **6:5 to 6:7**
- Exhaustion defense, **6:29**
- Experimental use defense, **6:26**
- Expiration issues, **6:22**
- Extension of patent term, **6:23**
- Federal authorization and consent, **6:32**
- Festo decision, **6:6, 6:7**
- File wrapper estoppel, **6:5 to 6:7**
- First inventor defense (1999 to 2011), **6:30**
- GATT implementing legislation, **6:19**
- Geographic scope of U.S. patents, **6:25**
- Guarantees of patent term, **6:20**
- Hormones. Growth hormones, above
- Immunology
 - classical immunology infringement cases, **6:10**
 - molecular immunology infringement cases, **6:12**
- Inducement. Active inducement and contributory infringement, above
- International matters
 - GATT implementing legislation, **6:19**
 - International Trade Commission, enforcement of patent rights by, **6:34**
- Interpretation of claim in biotechnology patent infringement litigation,

INFRINGEMENT—Cont'd

- tion, **6:8 to 6:13.50**
 - Intervening rights, **6:24**
 - Issuance issues, generally, **6:22**
 - Limitations, **6:26 to 6:32**
 - Literal infringement, **6:2**
 - Medical and surgical procedures, limitations on infringement of patents on, **6:31**
 - Medical device infringement cases, **6:13.50**
 - Microbiology infringement cases, **6:9**
 - Miscellaneous biotechnology infringement cases, **6:13**
 - Molecular biology infringement cases, **6:11**
 - Molecular immunology infringement cases, **6:12**
 - Pandemic Readiness and Emergency Preparedness Act
 - contractor immunity, **6:36**
 - Pharmaceutical infringement cases, **6:13.50**
 - Pharmaceutical testing and Section 271(e)(1) defense, **6:27**
 - Plants and Plant Patents** (this index)
 - Prior activity-based personal defenses, **6:30, 6:30.50**
 - Process patents, **6:16**
 - Product patents, **6:15**
 - Proinsulin vector, **6:18**
 - Provisional rights, **6:21**
 - Reissues and intervening rights, **6:24**
 - Reverse doctrine of equivalents, **6:4**
 - Section 271(e)(1) defense and pharmaceutical testing, **6:27**
 - Section 271(e)(2), filing ANDA or paper NDA, **6:28**
 - Sham litigation, antitrust matters, **6:35**
 - Surgical procedures, limitations on infringement of patents on, **6:31**
 - Temporal scope of U.S. patents, **6:19 to 6:24**
- INJURIOUS INVENTIONS**
- Disclosure, **5:19 to 5:20.10**

INDEX

INTERFERENCE PRACTICE

- Authentication, **8:37.30**
- Corroboration, **8:37.20**
- Count, **8:37.40**
- Pre-America Invents Act (AIA), **8:37**
- 35 U.S.C.A. Section 135(b) requirements, **8:37.10**

INTERNATIONAL MATTERS

- Generally, **13:1 et seq.**
- Antitrust matters, **13:13 to 13:17**
- Australia, **13:15**
- Canada, **13:17**
- Eastern bloc, statutory protection in, **13:1**
- France, **13:19**
- GATT** (this index)
- Germany, Federal Republic of** (this index)
- Great Britain, **13:11, 13:12**
- Infringement** (this index)
- Ireland, **13:16**
- Japan, **13:18**
- Licenses and licensing, **10:31**
- Monopolies, **13:13 to 13:17**
- New Zealand, **13:14**
- Office of Patent and Trademark** (this index)
- Plants and Plant Patents** (this index)
- Third world, statutory protection in, **13:3**
- Western block, statutory protection in, **13:2**

INTERNATIONAL TRADE COMMISSION

- Infringement, **6:34**

INTER PARTES REEXAMINATION PROCEDURE

- Office of Patent and Trademark, **8:35**

INTER PARTES REVIEW

- Office of Patent and Trademark, post-AIA, **8:41**

INTERPRETATION

- Infringement litigation, interpretation of claim in, **6:8 to 6:13**

INTERVENING ART

- Novelty, nonobviousness and double patenting, **4:26**

INTERVENING RIGHTS

- Infringement, **6:24**

INVENTORSHIP

- Ownership, **10:1 to 10:10.50**

IN VITRO DATA

- Disclosure, **5:18**

IRELAND

- Microbiology cases, **13:16**

ISOLATED AND MUTATED MICROORGANISMS

- Claim drafting, pure cultures of microbial isolates, **7:32**
- Disclosure** (this index)
- Patents, **1:2**

ISOLATION METHODS

- Claim drafting, **7:31**

JAPAN

- Generally, **13:18**

“JEPSON” CLAIMS

- Claim drafting, **7:14**

JOINT INVENTORSHIP

- Ownership, **10:10.50**

KNOWLEDGE

- Novelty, nonobviousness and double patenting, knowledge and suggestions of others, **4:47 to 4:50**

KSR CASE

- Novelty, nonobviousness and double patenting, **4:4.50, 4:5**

LABORATORIES

- Novelty, nonobviousness and double patenting: laboratory versus field testing, **4:40**

LANGUAGE USED IN CLAIMS

- Suggestions for resolution of apparent ambiguities created by use of percentage sequence identity language, **App H23**

LENGTH

Office of Patent and Trademark,
sequence listing, **App F2(5)**

LIBRARY COLLECTIONS

Novelty, nonobviousness and double
patenting, **4:30**

LICENSES AND LICENSING

Generally, **10:11 to 10:34**
Antitrust considerations, **10:32**
Biotechnology cases, **10:33**
Case law, **10:33**
Collaboration, **10:25**
Consideration, **10:19 to 10:23**
Disclosure, **10:28**
Extension of patent term, **10:27**
Federal licensing, generally, **10:30**
Identifying licensed rights, **10:10**
Implied license, **10:34**
International licensing, **10:31**
License to government, **10:35**
Maintenance, **10:26**
Milestone payments/timetables,
10:22
Minimum royalties, **10:21**
Prosecution, **10:26**
Relaxation of payment obligations,
10:23
Royalties, **10:20, 10:21**
Running royalties, **10:20**
Shop rights license, implied obliga-
tion to assign, **10:5**
Technical assistance, **10:25**
Termination, **10:24**
Time
generally, **10:13**
extension of patent term, **10:27**
milestone payments/timetables,
10:22
University licensing, **10:29**

**“LIFE FORM” PATENTS AND
HUMAN SOCIETY**

Patentability of living organisms,
2:12

**LIMITATIONS AND
RESTRICTIONS**

Claim drafting, **7:7 to 7:8.50**

**LIMITATIONS AND
RESTRICTIONS—Cont’d**

Contractual restrictions, tangible
materials, **14:18**
Disclosure, restrictions on public
availability, **5:48 to 5:52**
Infringement, **6:26 to 6:32**
Medical procedures, Appropriations
Bill (HR 3610) containing
patent limitations on, **App H13**
Obviousness, limitations on, **4:16.30,**
4:50
Office of Patent and Trademark, **8:20**
to 8:26

LINKING CLAIMS

Office of Patent and Trademark, **8:23**

LISTS AND LISTING

Sequence Listings (this index)

LITERAL INFRINGEMENT

Generally, **6:2**

LIVING ORGANISMS

Patents, **3:4**

LOYALTY DUTY

Ownership, implied obligation to
assign, **10:4**

LUNDAK CASE

Disclosure, **5:40 to 5:43**

MACROBIOLOGICAL PRODUCTS

Patent eligibility issues, nonliving,
3:5

MAINTENANCE

Licenses and licensing, **10:26**

MANUAL OF PATENT

EXAMINING PROCEDURE

Deposit of microorganisms, MPEP
§ 608.01(p), **App A1**
DNA, MPEP § 708.02, petition to
make special (Section VII.
inventions relating to
recombinant DNA), **App H6**

MARKS AND MARKING

Plants and plant patents, marking of
protected varieties, **11:20**

INDEX

“MARKUSH GROUP” CLAIMS

Claim drafting, **7:13**

MATHEMATICAL STEPS

Processes involving, patent eligibility issues, **3:14**

MEDICAL AND SURGICAL PROCEDURES

Appropriations Bill (HR 3610) containing patent limitations on, **App H13**

Infringement, limitations on, **6:31**

MEDICAL DEVICE CASES

Disclosure, **5:28.50**

Infringement, **6:13.50**

Nonobviousness standard, **4:21.50**

MEETINGS

Novelty, nonobviousness and double patenting, **4:29**

MENTAL STEPS

Processes involving, patent eligibility issues, **3:14**

MICROBIOLOGY CASES

Canada, **13:17**

Claim drafting, **7:25 to 7:38**

Classical microbiology infringement cases, **6:9**

Disclosure, **5:7.10, 5:24, 5:66**

Great Britain, **13:11, 13:12**

Ireland, **13:16**

Nonobviousness standard, **4:17**

MICROORGANISMS

Deposit of Microorganisms (this index)

Great Britain, **13:11, 13:12**

Isolated and Mutated Microorganisms (this index)

Novelty, nonobviousness and double patenting, released microorganisms: laboratory versus field testing, **4:40**

PTO notice re. microorganisms—patentable subject matter, **App H1**

MILESTONE

PAYMENTS/TIMETABLES

Licenses and licensing, **10:22**

MINIMUM ROYALTIES

Licenses and licensing, **10:21**

MIXED CULTURES

Claim drafting, **7:33**

MOLECULAR BIOLOGY CASES

Claim drafting, **7:15 to 7:18**

Disclosure, **5:7.30, 5:26, 5:64**

Infringement cases, **6:11**

Nonobviousness standard, **4:19**

MOLECULAR IMMUNOLOGY CASES

Disclosure, **5:27**

Nonobviousness standard, **4:20**

MOLECULES

Copyright protection for gene sequences or molecules, **14:2 to 14:9**

MONOCLONAL ANTIBODIES

Claim drafting, **7:20**

MONOPOLIES

Antitrust Matters (this index)

MOTIVATION

Nonobviousness, standard of, **4:7**

MPEP

Manual of Patent Examining Procedure (this index)

MUTATED MICROORGANISMS

Claim drafting, **7:35, 7:36**

Isolated and Mutated Microorganisms (this index)

NASA-SPONSORED INVENTIONS

Ownership, **10:8**

NATURE, LAWS AND PRODUCTS OF

Patent eligibility issues, **3:1 to 3:12**

NEGATIVE LIMITATIONS

Claim drafting, **7:8**

NEGATIVE TEACHINGS

Nonobviousness standard, negative teachings on expectations of success, **4:11**

NEW DRUG APPLICATION

Infringement, filing ANDA or paper NDA as infringing act, **6:28**

NEWLY FOUND PLANTS VERSUS NEWLY CREATED PLANTS

Generally, **11:5**

NEW ZEALAND

Generally, **13:14**

1952 PATENT ACT

Novelty, nonobviousness and double patenting introduction, **4:1.30**
prior art, **4:23.30**

1992 PATENT ACT

Novelty, nonobviousness and double patenting documentary prior art—U.S. practice, **4:34**
2002 amendments, **4:34**

NONDOCUMENTARY PRIOR ART

Novelty, nonobviousness and double patenting, **4:35 to 4:50**

NONOBVIOUSNESS

Novelty, Nonobviousness and Double Patenting (this index)

NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

Generally, **4:1 et seq.**
Abandonment, suppression, or concealment, **4:45**
America Invents Act (AIA) of 2011 documentary prior art, U.S. practice, **4:34.50**
effect of, **4:16.70**
introduction, **4:1.70**
prior art, **4:23.70**
Animal testing versus clinical testing, **4:39**
Appreciation, **4:44**
Artificial Intelligence, **4:51**

NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

—Cont'd

Biotechnology novelty cases, misc., **4:3.40**
Cell biology cases, nonobviousness standard, **4:17**
Cell biology novelty cases, **4:3.10**
Chemical cases nonobviousness standard, **4:21.60**
novelty standard, **4:3**
compounds, structural similarities of, **4:6**
Classical microbiology novelty cases, **4:3.10**
Clinical testing versus animal testing, **4:39**
Competing approaches, **4:13**
Concealment, **4:45**
Conception, **4:42**
Conferences, **4:29**
Confidential documents, **4:31**
Copyright protection, novel gene sequences, **14:5, 14:9**
Critical date (pre AIA), **4:25**
Dates critical date (pre AIA), **4:25**
date of invention (pre AIA), **4:24.50**
effective filing date, **4:25.50**
state of the art date, **4:24, 4:24.50**
Defense of prior invention, **4:46**
Diligence, **4:43**
Documentary prior art, **4:27 to 4:34.50**
Effective filing date, **4:25.50**
Electronic publications, **4:32**
“Enabling” character, **4:27**
Expectation of success, standard of nonobviousness, **4:10 to 4:12**
Immunology cases, nonobviousness standard, **4:18, 4:20**
Immunology novelty cases, **4:3.30**
Intervening art, **4:26**
Knowledge and suggestions of others, **4:47 to 4:50**

INDEX

NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

—Cont'd

- KSR case
 - obviousness analysis, **4:5**
 - pre-KSR teaching-suggestion-motivation test, **4:4.50**
- Library collections, **4:30**
- Limitations on obviousness, **4:16.30, 4:50**
- Medical device cases, nonobviousness standard, **4:21.50**
- Medical device novelty cases, **4:3.50**
- Meetings, **4:29**
- Microbiology cases, nonobviousness standard, **4:17**
- Molecular biology, **4:3.20**
- Molecular biology cases,
 - nonobviousness standard, **4:19**
- Molecular immunology cases,
 - nonobviousness standard, **4:20**
- Motivation, standard of nonobviousness, **4:7**
- Negative teachings on expectations of success, **4:11**
- 1952 Patent Act
 - introduction, **4:1.30**
 - prior art, **4:23.30**
- 1992 Patent Act and 2002 amendments, documentary prior art—U.S. practice, **4:34**
- Nondocumentary prior art, **4:35 to 4:50**
- Pharmaceutical cases, nonobviousness standard, **4:21.50**
- Pharmaceutical novelty cases, **4:3.50**
- Plant patent protection, **11:7, 11:9**
- Prima facie obviousness, **4:6 to 4:13**
- Printed publications, **4:28 to 4:32**
- Prior art
 - generally, **4:22 to 4:26**
 - documentary prior art, **4:27 to 4:34.50**
 - interim examination guidelines for species claims to chemical compositions based on single prior art reference, **App H14**
 - 1952 Patent Act, **4:23.30**

NOVELTY, NONOBVIOUSNESS AND DOUBLE PATENTING

—Cont'd

- Prior art—Cont'd
 - 1992 Patent Act and 2002 amendments, U.S. practice, **4:34**
 - nondocumentary prior art, **4:35 to 4:50**
 - pre-2000 practice in U.S., **4:33**
 - 2011 America Invents Act, **4:23.70, 4:34.50**
 - U.S. patents and applications, **4:33 to 4:34.50**
- Prior invention of another, **4:37 to 4:46**
- Prior use and sale, **4:36**
- Processes, nonobviousness standard, **4:16**
- Protein chemistry, **4:3.20**
- Reduction to practice, **4:37.50 to 4:41**
- Released microorganisms: laboratory versus field testing, **4:40**
- Sale, prior use and sale, **4:36**
- “Secondary considerations,”
 - nonobviousness standard, **4:15**
- Secret documents, **4:31**
- Seminars, **4:29**
- Similarities, structural similarities of chemical compounds, **4:6**
- Standards
 - biotechnology novelty cases, misc., **4:3.40**
 - cell biology novelty cases, **4:3.10**
 - classical microbiology novelty cases, **4:3.10**
 - immunology novelty cases, **4:3.30**
 - medical device novelty cases, **4:3.50**
 - molecular biology, **4:3.20**
 - nonobviousness, **4:4 to 4:21.60**
 - novelty, **4:2, 4:3**
 - biotechnology novelty cases, misc., **4:3.40**
 - cell biology novelty cases, **4:3.10**
 - classical microbiology novelty cases, **4:3.10**

**NOVELTY, NONOBVIOUSNESS
AND DOUBLE PATENTING**

—Cont'd

- Standards—Cont'd
 - novelty, **4:2, 4:3**—Cont'd
 - immunology novelty cases, **4:3.30**
 - medical device novelty cases, **4:3.50**
 - molecular biology, **4:3.20**
 - pharmaceutical novelty cases, **4:3.50**
 - protein chemistry, **4:3.20**
 - pharmaceutical novelty cases, **4:3.50**
 - prima facie obviousness, **4:6 to 4:13**
 - protein chemistry, **4:3.20**
 - “secondary considerations,” **4:15**
 - “unexpected results,” **4:14**
 - State of the art date, **4:24, 4:24.50**
 - Statutory limitations on obviousness, **4:16.30**
 - Structural similarities of chemical compounds, **4:6**
 - Suggestions of others, **4:47 to 4:50**
 - Suppression or concealment, **4:45**
 - Teaching-suggestion-motivation test, nonobviousness standard, **4:4.50**
 - Theory of “inventorship entity,” **4:23**
 - Timing. Dates, above
 - Trade shows, **4:29**
 - “Unexpected results,” nonobviousness standard, **4:14**
 - Unrealistic expectations of success, **4:12**
 - Utility, standard of nonobviousness, **4:7**
 - Vaccine cases, **4:41**

NUCLEIC ACID

- Office of Patent and Trademark, sequences, **App F2(12)**

NUCLEOTIDE COMBINATIONS

- Copyright protection, **14:8**

NUCLEOTIDE SEQUENCES

- Examination and examination guidelines, **App H27**

NUCLEOTIDE SEQUENCES

—Cont'd

- PTO final rule for submitting, **App H16**
- Representation, **8:10**
- Sequence Listings** (this index)

NUMBERS AND NUMBERING

- Plants and plant patents, number of claims, **11:16**

NUTRIENT MEDIA

- Claim drafting, **7:27**

OBVIOUSNESS

- Novelty, Nonobviousness and Double Patenting** (this index)

**OFFICE OF PATENT AND
TRADEMARK**

- 1990 and 1998 Sequence Listing Rules, **App F2**
- AIA. 2011 America Invents Act (AIA), below
- America Invents Act (AIA) of 2011
 - derivation proceedings and derived patent suits, **8:38**
 - inter partes review, **8:41**
 - post-grant review, **8:40**
 - supplemental examination, **8:39**
- Amino acid sequences, **App F2(11)**
- Applications
 - coverage, **8:5**
 - foreign filed applications, domestic publication of, **8:34**
 - provisional applications, **8:29, 8:30**
 - sequence listing rules
 - 1990, **8:4.10**
 - 1998, **8:4.20**
- Atomic Energy Act, **8:27**
- Authentication, interference practice, **8:37.30**
- Continued examination, **8:33**
- Corroboration, interference practice, **8:37.20**
- Count, interference practice, **8:37.40, 8:40**
- Deposit of Microorganisms** (this index)
- Disclosure** (this index)

**OFFICE OF PATENT AND
TRADEMARK—Cont'd**

Distinct inventions, **8:22**
 Drafting considerations, **8:2 to 8:18.50**
 Drawings, **8:16 to 8:18.50**
 Equitable conduct, standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**
 Examination
 continued examination, **8:33**
 deposit of microorganisms: Manual of Patent Examining Procedure § 608.01(p), **App A1**
 optional inter partes reexamination procedure, **8:35**
 utility and utility patents, below **Written Description** (this index)
 Ex parte Chakrabarty, proceedings before patent office, **2:3**
 Final PTO utility examination guidelines, **App H9**
 Final rejection, **8:32**
 Final rule for submitting nucleotide sequences, **App H16**
 Formal drawings, **8:16 to 8:18.50**
 Formal processing, **App F2(13)**
 GATT, post-GATT transitional practice, **8:26, 8:32**
 Genetic inventions, PTO policy statement on, **App H22**
 Genus and species restrictions, **8:25**
 Guidelines
 examination of patent applications under 35 U.S.C. 122, written description requirement, **App H25**
 patent eligibility issues, **3:17**
 Independent inventions, **8:21**
 Inequitable conduct
 cases, **8:31.50**
 standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**
 Interference practice
 authentication, **8:37.30**
 corroboration, **8:37.20**
 count, **8:37.40**

**OFFICE OF PATENT AND
TRADEMARK—Cont'd**

Interference practice—Cont'd
 pre-AIA, **8:37**
 35 U.S.C.A. Section 135(b) requirements, **8:37.10**
 International matters
 GATT, post-GATT transitional practice, **8:26, 8:32**
 publication of foreign filed applications, **8:34**
 Inter partes reexamination procedure, **8:35**
 Length of sequence listing, **App F2(5)**
 Linking claims, **8:23**
 Notices
 animals—patentability, **App H4**
 microorganisms—patentable subject matter, **App H1**
 petitioning to make applications relating to biotechnology special, **App H5**
 plant life—patentable subject matter, **App H3**
 Nucleic acid sequences, **App F2(12)**
 Nucleotide sequences, PTO final rule for submitting, **App H16**
 Optional inter partes reexamination procedure, **8:35**
 Petitions
 generally, **8:19**
 MPEP § 708.02, petition to make special (Section VII. inventions relating to recombinant DNA), **App H6**
 notice, petitioning to make applications relating to biotechnology special, **App H5**
 Photographic figures, **8:17**
 Post-GATT transitional practice, **8:26, 8:32**
 Post-grant review, post-AIA, **8:40**
 Post-issuance considerations, **8:35**
 Practice and procedure, generally, **8:1 et seq.**
 Prioritized examination, **8:18.50**
 Prosecution considerations, generally, **8:19 to 8:41**

**OFFICE OF PATENT AND
TRADEMARK—Cont'd**

- Provisional applications, **8:29, 8:30**
- Publication of foreign filed applications, **8:34**
- Reexamination, inter partes reexamination procedure, **8:35**
- Rejection, **8:32**
- Rejoinder of method claims to product claims, **8:24**
- Restrictions, **8:20 to 8:26**
- Sequence Listings** (this index)
- Species restrictions, **8:25**
- Standards of inequitable conduct in biotechnology patent and prosecution litigation, **8:31**
- Strandedness of sequence listings, **App F2(7)**
- Support of government, mention of, **8:3**
- Suspension of prosecution, **8:28**
- 35 U.S.C.A. Section 135(b) requirements, interference practice, **8:37.10**
- Topology of sequence listings, **App F2(8)**
- Utility and utility patents
 - examination and examination guidelines
 - generally, **App H26**
 - final PTO utility examination guidelines, **App H9**
 - nucleotide sequences, **App H27**
 - proposed utility examination guidelines at 60 FR 97, **App H10**
 - revised interim utility guidelines training materials, **App H21**
 - revised utility examination guidelines, request for comments, **App H20**
 - synopsis of utility examination guidelines, **App H11**
- Written Description** (this index)

OPERABLE INVENTIONS

- Disclosure, **5:12, 5:18, 5:21 to 5:28.50**

OPERATING CONDITIONS

- Claim drafting, **7:28**

OPTIONAL INTER PARTES

**REEXAMINATION
PROCEDURE**

- Office of Patent and Trademark, **8:35**

ORGAN CULTURES

- Claim drafting, **7:38**
- Patents, **1:5**

**“ORGANISM-PLUS-CARRIER”
CLAIMS**

- Claim drafting, **7:34**

ORNAMENTAL FEATURES

- Animals and plants, design patent protection of ornamental features of, **9:5**

ORPHAN DRUG ACT

- Exclusive drug approvals, **14:15**

OWNERSHIP

- Generally, **10:1 et seq.**
- Assignment, **10:2 to 10:5**
- Correction of inventorship errors, **10:1.50**
- Employees
 - federal government employees, inventions made by, **10:10**
 - implied obligation to assign, **10:3**
- Energy inventions, **10:7**
- Federal government employees, inventions made by, **10:10**
- Federal statutes, **10:7 to 10:10**
- Implied obligation to assign, **10:3 to 10:5**
- Inventorship, generally, **10:1 to 10:1.50**
- Joint inventorship, **10:10.50**
- Loyalty duty, implied obligation to assign, **10:4**
- NASA-sponsored inventions, **10:8**
- Plants and plant patents, **11:12**
- Shop rights license, implied obligation to assign, **10:5**
- State statutes, **10:6**
- Support of government, inventions made with, **10:9**

INDEX

OWNERSHIP—Cont'd

- Testing of compounds, inventorship, **10:1.10**
- Unexpected results, inventorship, **10:1.20**
- Written description or utility, inventorship, **10:1.30**

PANDEMIC READINESS AND EMERGENCY PREPAREDNESS ACT

- Infringement contractor immunity, **6:36**

PATENT AND TRADEMARK OFFICE

- Office of Patent and Trademark (this index)

PATENT COOPERATION TREATY

- Deposit of Microorganisms (this index)

PATENT ELIGIBILITY ISSUES

- Generally, **2:1 et seq.**
- Antibodies, **3:7**
- Bergy decision, **2:4, 2:5**
- Biochemicals, **3:8**
- CCPA, **2:5 to 2:7**
- Cells in vitro, non fermentation process, **3:12**
- Chakrabarty decision, **2:6, 2:8**
- Computer-implemented steps, processes involving, **3:14**
- Consolidation of proceedings, **2:7**
- Crystalline paroxetine hydrochloride hemihydrate, **3:16**
- Diagnostic methods, **3:11**
- DNA, **3:6**
- Early developments, **2:2**
- Ex parte Chakrabarty, proceedings before Office of Patent and Trademark, **2:3**
- Ex parte matters, **2:3, 2:4**
- Fermentation, **3:10**
- Flook decision and “unforeseen technologies,” **2:9**
- Guidelines, PTO, **3:17**
- Human organisms, **2:14**
- “Life form” patents and human society, **2:12**

PATENT ELIGIBILITY ISSUES

—Cont'd

- Living organisms, **3:4**
 - biotechnology, U.S. materials on, **App H8**
 - per se, **2:1 et seq.**
 - subject matter, U.S. materials on, **App H2**
- Macrobiological products, nonliving, **3:5**
- Mathematical steps, processes involving, **3:14**
- Mental steps, processes involving, **3:14**
- Nature, laws and products of, **3:1 to 3:12**
- Non fermentation process, cells in vitro, **3:12**
- Nonliving macrobiological products, **3:5**
- Other chemicals, **3:8**
- Peptides, **3:7**
- Plants and plant patents, **2:10**
- Printed matter, **3:15**
- Processes involving mental, mathematical or computer-implemented steps, **3:14**
- Proteins, **3:7**
- Remand, **2:7**
- RNA, **3:6**
- Static v. dynamic construction, **2:11**
- Statutory subject matter, **2:1**
- Supreme Court, **2:7, 2:8, 3:2**
- Treatment methods, **3:13**
- Unforeseen technologies, **2:9**
- Vitalism, **2:13**

PATENTS

- As to particular patent matters, see specific index topics
- Generally, **1:1 et seq.**
- Cell cultures, **1:5, 1:6**
- Eligibility. **Patent Eligibility Issues** (this index)
- European Patent Convention** (this index)
- Extension of Patent Term** (this index)
- Fundamental patent law concepts, **1:8**

PATENTS—Cont'd

- Genetic Engineering** (this index)
- Hybrid cell cultures, **1:6**
- Infringement** (this index)
- Isolated and mutated microorganisms, **1:2**
- Mutated microorganisms, **1:2**
- Novelty, Nonobviousness and Double Patenting** (this index)
- Office of Patent and Trademark** (this index)
- Organ cultures, **1:5**
- Plants and Plant Patents** (this index)
- Tissue cultures, **1:5**
- Trade secrets, patents, and genetic engineering industry, **1:7**
- Utility and Utility Patents** (this index)
- Vaccines** (this index)

PEDIATRIC EXCLUSIVITY

- Protection for biotechnology, **14:16**

PEOPLE

- Patentability of living organisms, **2:14**

PEPTIDES

- Patent eligibility issues, **3:7**

**PERCENTAGE SEQUENCE
IDENTITY LANGUAGE**

- Metes and bounds of claims reciting, **App H24**
- Suggestions for resolution of apparent ambiguities created by use in claims, **App H23**

PETITIONS

- Office of Patent and Trademark** (this index)

PHARMACEUTICAL CASES

- Disclosure, **5:28.50**
- Infringement, **6:13.50**
- Nonobviousness standard, **4:21.50**

PHARMACEUTICAL TESTING

- Infringement, Section 271(e)(1) defense, **6:27**

PHOTOGRAPHIC FIGURES

- Office of Patent and Trademark, **8:17**

PLANTS AND PLANT PATENTS

- Generally, **11:1 et seq.**
- Active inducement and contributory infringement, **11:21**
- “Asexually reproduced” varieties, **11:10**
- Bacteria, **11:3**
- Breadth of claims, **11:16**
- Changes in plant patent protection under UPOV, **11:23**
- Claims for plant products, generally, **11:15**
- Comparison of plant variety protection methods, **12:5**
- Conception and reduction to practice, **11:13**
- Contributory infringement, **11:21**
- Conventions, plant patent protection outside of, **13:4**
- Copyright protection for plant and animal phenotypes, **14:10**
- Courts, application of PVPA in, **12:3**
- “Cultivated state,” varieties found in, **11:11**
- Derivation as element of infringement, **11:18**
- Disclosure requirements, **11:14**
- Distinctness
 - generally, **11:8**
 - infringement, **11:19**
- European Patent Convention, examination guidelines, plant or animal varieties excluded from patentability, **App J3**
- Infringement, generally, **11:17**
- International matters
 - conventions, plant patent protection outside of, **13:4**
 - UPOV countries, plant variety protection in, **12:6**
- Marking of protected varieties, **11:20**
- Newly found plants versus newly created plants, **11:5**
- Novelty and nonobviousness, **11:7, 11:9**
- Number and breadth of claims, **11:16**

INDEX

PLANTS AND PLANT PATENTS

—Cont'd

- Ownership, **11:12**
- Patentability of living organisms, **2:10**
- Plant variety protection
 - certificate application, **App G4**
 - office, **12:4**
- PTO notice, plant life—patentable subject matter, **App H3**
- Restoration of plant patent term, **11:22**
- Scope of variety protection, **12:2**
- Tuber-propagated plants, **11:4**
- Union for protection of new varieties of plants. UPOV, below
- UPOV
 - generally, **12:1 et seq.**
 - changes in plant patent protection under UPOV, **11:23**
- Utility patents, **9:1 to 9:3, 9:5**
- Variety protection. **Plant Variety Protection Materials** (this index)

PLANTS PATENT ACT

- Generally, **11:2 to 11:5**

PLANT VARIETY PROTECTION MATERIALS

- Application for plant variety protection certificate, **App G4**
- Guidelines
 - Exhibit A: Origin and Breeding history, **App G3(A)**
 - Exhibit B: Statement of distinctness, **App G3(B)**
 - Exhibit E: Statement of the basis of ownership, **App G3(E)**
- PVPA regulations and rules of practice, **App G2**
- United States Plant Variety Protection Act, generally, **App G1**

POSTFILING DEPOSITS

- Disclosure, **5:43**

POST-GATT TRANSITIONAL PRACTICE

- Office of Patent and Trademark, **8:26, 8:32**

POST-GRANT REVIEW

- Office of Patent and Trademark, post-AIA, **8:40**

POST-ISSUANCE

CONSIDERATIONS

- Office of Patent and Trademark, **8:35**

PREAMBLE LIMITATIONS

- Claim drafting, **7:8.50**

PRESUMPTIONS

- Disclosure, presumption of utility, **5:13**

PRIMA FACIE CASE OR MATTERS

- Disclosure, prima face case of inoperability, **5:13**
- Nonobviousness, standard of, **4:6 to 4:13**

PRINTED MATTER

- Patent eligibility issues, **3:15**

PRINTED PUBLICATIONS

- Novelty, nonobviousness and double patenting, **4:28 to 4:32**

PRIOR ART

- Novelty, Nonobviousness and Double Patenting (this index)

PRIOR INVENTION OF ANOTHER

- Novelty, nonobviousness and double patenting, **4:37 to 4:46**
- Reduction to practice
 - generally, **4:37.50 to 4:41**
 - actual, **4:38**
 - animal versus clinical testing, **4:39**
 - constructive, **4:37.50**
 - early vaccine cases, **4:41**
 - released microorganisms, **4:40**

PRIOR USE AND SALE

- Novelty, nonobviousness and double patenting, **4:36**

PROCESSES

- Claim drafting, “product-by-process” claims, **7:10 to 7:12**
- Infringement, process patents, **6:16**
- Mental, mathematical or computer-implemented steps, patent

- PROCESSES—Cont’d**
 eligibility issues, **3:14**
 Nonobviousness standard, **4:16**
- PRODUCT PATENTS**
 Infringement, **6:15**
 New processes and uses, coverage of, **6:15**
- PROINSULIN VECTOR**
 Infringement, **6:18**
- PROOF**
 Disclosure (this index)
- PROSECUTION CONSIDERATIONS**
 Licenses and licensing, **10:26**
 Office of Patent and Trademark (this index)
- PROTEINS**
 Claim drafting, structural genes and their proteins, identification of, **7:16**
 Copyright protection, **14:6**
 Patent eligibility issues, **3:7**
- PROVISIONAL APPLICATIONS**
 Office of Patent and Trademark, **8:29, 8:30**
- PROVISIONAL RIGHTS**
 Infringement, **6:21**
- PTO**
 Office of Patent and Trademark (this index)
- PUBLICATION**
 Office of Patent and Trademark, domestic publication of foreign filed applications, **8:34**
- PUBLIC POLICY**
 Disclosure, inventions contrary to public policy, **5:19, 5:20**
- PURE CULTURES OF MICROBIAL ISOLATES**
 Claim drafting, **7:32**
- REAGENTS**
 Claim drafting, **7:24**
- “RED DOVE” CASE**
 Germany, Federal Republic of, **13:6**
- REEXAMINATION**
 Office of Patent and Trademark, inter partes reexamination procedure, **8:35**
- REISSUES**
 Infringement, **6:24**
- REJECTION**
 Office of Patent and Trademark, **8:32**
- REJOINER**
 Office of Patent and Trademark, rejoinder of method claims to product claims, **8:24**
- RELEASED MICROORGANISMS**
 Novelty, nonobviousness and double patenting: laboratory versus field testing, **4:40**
- REMAND**
 Patent eligibility issues, **2:7**
- REPORTS AND REPORTING**
 Trilateral Project 24.1, comparative study/report on biotechnology patent practices, **App J5**
- RESTORATION**
 Plant patent term, **11:22**
- RESTRICTIONS**
 Limitations and Restrictions (this index)
- REVERSE DOCTRINE OF EQUIVALENTS**
 Infringement, **6:4**
- RNA**
 Patent eligibility issues, **3:6**
- “ROSE MUTATION” CASE**
 Germany, Federal Republic of, **13:8**
- ROYALTIES**
 Licenses and licensing, **10:20, 10:21**
- RUNNING ROYALTIES**
 Licenses and licensing, **10:20**

INDEX

SAFETY

Disclosure, unsafe inventions, **5:20**

SALES

Novelty, nonobviousness and double patenting, prior use and sale, **4:36**

“SECONDARY CONSIDERATIONS”

Nonobviousness standard, **4:15**

SECRET DOCUMENTS

Novelty, nonobviousness and double patenting, **4:31**

SEMINARS

Novelty, nonobviousness and double patenting, **4:29**

SEQUENCE LISTINGS

Generally, **App F**

Disclosure, **5:67 to 5:69**

Draft sequence listing rules, **App F1(1)**

Nucleotide sequence and/or amino acid sequence disclosures, requirements for patent applications containing

generally, 37 C.F.R. §§ 1.821 to 1.825, **App F1, App F1(6)**

PTO notices. Office of Patent and Trademark, below

Office of Patent and Trademark generally, **8:18**

amendments, 2021, **8:4.40**

amino acid representation, **8:11**

compact disc regulations, **8:4.30**
coverage, **8:5**

feature keys, **8:12**

format, **8:6**

general information, part of sequence listing XML, **8:7**

nucleotide sequence and/or amino acid sequence disclosures, requirements for patent applications containing notices

final rule, **App F1(3)**

proposed rules, **App F1(2), App F1(4)**

SEQUENCE LISTINGS—Cont’d

Office of Patent and Trademark

—Cont’d

nucleotide sequence and/or amino acid sequence disclosures, requirements for patent applications containing

—Cont’d

rules, **App F1(2), App F1(4), App F1(5)**

nucleotide sequence representation, **8:10**

rules, 1990, **8:4.10**

rules, 1998, **8:4.20**

sequence data, part of sequence listing XML, **8:8**

sequence representation, generally, **8:9**

transition, WIPO Standard ST.26, **8:4.50**

XML, **8:7, 8:8, 8:13, 8:14**

Percentage Sequence Identity Language (this index)

Standard for presentation of nucleotide and amino acid, using extensible markup language in patent applications, **App F3**

SHAM LITIGATION

Infringement, antitrust matters, **6:35**

SIMILARITIES

Nonobviousness standard, structural similarities of chemical compounds, **4:6**

“6-APA” CASE

Germany, Federal Republic of, **13:9**

SPECIAL CLAIM FORMATS

Claim drafting, **7:9 to 7:14**

SPECIES RESTRICTIONS

Office of Patent and Trademark, **8:25**

SPECIFIC AND SUBSTANTIAL UTILITY

Disclosure, **5:11**

SPECIFICATIONS

Disclosure, deposit of microbiological materials as means of

SPECIFICATIONS—Cont'd
 supplementing specification,
5:31 to 5:56

SPECIMENS
 Disclosure, PTO authority to require
 specimens, **5:62**

STANDARD OF PROOF
 Disclosure, standard of proof of oper-
 ability, **5:14**

STANDARDS
**Novelty, Nonobviousness and
 Double Patenting** (this index)
 Office of Patent and Trademark, stan-
 dards of inequitable conduct in
 biotechnology patent and prose-
 cution litigation, **8:31**

**STATIC v. DYNAMIC
 CONSTRUCTION**
 Patentability of living organisms,
2:11

STRANDEDNESS
 Office of Patent and Trademark,
 sequence listing, **App F2(7)**

**STRUCTURAL GENES AND
 THEIR PROTEINS**
 Claim drafting, identification, **7:16**

STRUCTURAL SIMILARITIES
 Nonobviousness standard, structural
 similarities of chemical
 compounds, **4:6**

STUDIES
 Trilateral Project 24.1, comparative
 study on biotechnology patent
 practices, **App J5**

SUBSTANTIAL UTILITY
 Disclosure, **5:11**

SUGGESTIONS
 Novelty, nonobviousness and double
 patenting, knowledge and sug-
 gestions of others, **4:47 to 4:50**

SUPPLEMENTAL EXAMINATION
 America Invents Act (AIA) of 2011,
8:39

SUPPLEMENTARY PROTECTION
 Claim drafting, **7:29**

SUPPORT OF GOVERNMENT
 Office of Patent and Trademark, men-
 tion of government support, **8:3**
 Ownership, inventions made with
 government support, **10:9**

SUPPRESSION
 Novelty, nonobviousness and double
 patenting, **4:45**

SUPREME COURT
 Patentability of living organisms, **2:7,
 2:8**
 Patent eligibility issues, **3:2**

SURGICAL PROCEDURES
 Infringement, limitations on, **6:31**

SUSPENSION OF PROSECUTION
 Office of Patent and Trademark, **8:28**

TANGIBLE PROPERTY RIGHTS
 Cell lines, **14:11**

**TAXONOMIC CLASSIFICATION
 OF ORGANISMS**
 Claim drafting, **7:4**

TECH CENTER 1600
 Background information on examin-
 ing tech center 1600, biotechnol-
 ogy, **App H7**

TECHNICAL ASSISTANCE
 Licenses and licensing, **10:25**

**TEMPORAL SCOPE OF U.S.
 PATENTS**
 Infringement, **6:19 to 6:24**

TERMINATION
 Licenses and licensing, **10:24**

TEST KITS
 Claim drafting, **7:24**

THERAPEUTIC UTILITY
 Disclosure, **5:15, 5:16, 5:18**

THIRD WORLD
 Statutory protection, **13:3**

INDEX

TIME OR DATE

Disclosure, time or date when deposit must be made available to public, **5:45 to 5:47**

Extension of Patent Term (this index)

Infringement, extension of patent term, **6:23**

Licenses and Licensing (this index)

Novelty, Nonobviousness and Double Patenting (this index)

TISSUE CULTURES

Claim drafting, **7:38**

Patents, **1:5**

TITLE AND OWNERSHIP

Ownership (this index)

TOPOLOGY

Office of Patent and Trademark, sequence listings, **App F2(8)**

TRADE SECRETS

Generally, **14:1**

Patents and genetic engineering industry, **1:7**

TRADE SHOWS

Novelty, nonobviousness and double patenting, **4:29**

TRAINING MATERIALS

Disclosure, **5:6, 5:6.50**

Examining patent applications with respect to 35 U.S.C Section 112, chemical/biotechnical applications, **App H15**

Revised interim written description guidelines, **App H19**

2000 written description training materials, **5:6**

2008 written description training materials, **5:6.50**

TREATIES

Budapest Treaty (this index)

Disclosure, deposits under, **5:34, 5:50, 5:55, 5:60, 5:61**

TREATMENT METHODS

Patent eligibility issues, **3:13**

TUBER-PROPAGATED PLANTS

Generally, **11:4**

U. S. PATENT AND TRADEMARK OFFICE

Office of Patent and Trademark (this index)

“UNEXPECTED RESULTS”

Nonobviousness standard, **4:14**

UNFORESEEN TECHNOLOGIES

Patent eligibility issues, **2:9**

UNION FOR PROTECTION OF NEW VARIETIES OF PLANTS

Plants and Plant Patents (this index)

UNITED STATES PATENT AND TRADEMARK OFFICE

Office of Patent and Trademark (this index)

UNITED STATES PLANT VARIETY PROTECTION ACT

Plant Variety Protection Materials (this index)

UNIVERSITY LICENSING

Generally, **10:29**

UNREALISTIC EXPECTATIONS

Nonobviousness standard, unrealistic expectations of success, **4:12**

UNSAFE INVENTIONS

Disclosure, **5:20**

UNTRANSFORMED

EUKARYOTIC CELL CULTURES

Claim drafting, **7:37**

UPOV

Plants and Plant Patents (this index)

UTILITY AND UTILITY PATENTS

Animal varieties, **9:3 to 9:6**

Disclosure (this index)

Enablement, **5:20.10**

Guidelines generally, **App H26**

UTILITY AND UTILITY PATENTS

—Cont'd

- Guidelines—Cont'd
 - revised interim utility guidelines training materials, **App H21**
 - revised utility examination guidelines, request for comments, **App H20**
- Nonobviousness, standard of, **4:7**
- Office of Patent and Trademark** (this index)
- Plant patents, **9:1 to 9:3, 9:5**

VACCINES

- Generally, **1:4**
- Infringement** (this index)
- Novelty, nonobviousness and double patenting, **4:41**
- Patents, generally, **1:4**

VETERINARY UTILITY

- Disclosure, animal data as proof of veterinary utility, **5:17**

VIABILITY

- Disclosure, **5:53**

VITALISM

- Patent eligibility issues, **2:13**

WAXMAN-HATCH ACT

- Drug approvals, **14:12**

WELL-ESTABLISHED UTILITY

- Disclosure, **5:10**

WESTERN BLOCK

- Statutory protection, **13:2**

WIPO STANDARD ST.25

- Generally, **App J4**
- Adoption of updated, revision to incorporation by reference, **App F3(1)**

WRITTEN DESCRIPTION

- Disclosure, **5:2.10, 5:5, 5:63 to 5:66**
- Examination of patent applications under 35 U.S.C. 112. See entries throughout this topic
- Guidelines for examination of patent applications under 35 U.S.C. 122, **App H25**
- Office of Patent and Trademark. See entries throughout this topic
- Request for comments on interim guidelines for examination of patent applications under 35 U.S.C. 112 “written description” requirement, **App H17, App H18**
- Revised interim written description guidelines, training materials, **App H19**
- Training materials, revised interim written description guidelines, **App H19**